BRCA1, a potential predictive biomarker in the treatment of breast cancer
BRCA1, a potential predictive biomarker in the treatment of breast cancer
复制标题
DOI：
10.1634/theoncologist.12-2-142
复制
发表时间：
2007-01-01
期刊：
影响因子：
5.8
通讯作者：
Harkin, D. Paul
中科院分区：
文献类型：
--
作者：
James, Colin R.;Quinn, Jennifer E.;Harkin, D. Paul
迄今为止，雌激素受体、孕激素受体和HER 2/neu代表了目前在常规临床实践中用于辅助治疗决策的分子生物标志物。在过去的几年里，大量的临床前和回顾性临床数据已经积累，表明BRCA 1突变作为一种新的预测化疗反应的标志物。本文综述了BRCA 1作为乳腺癌化疗反应的预测标志物的作用，并探讨了BRCA 1缺陷和基底样表型之间的联系。搜索策略。通过MEDLINE和PubMed检索已发表的报告，使用术语BRCA 1、乳腺癌、基底样、化疗、预后和预测标志物确定本文的数据。在某些情况下，由于篇幅的限制，读者会被推荐阅读综述文章，以便进一步阅读。仅纳入英文发表的文章。
To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of preclinical and retrospective clinical data has accumulated that suggests that BRCA1 mutation functions as a novel predictive marker of response to chemotherapy. This article reviews the role of BRCA1 as a predictive marker of chemotherapy response in breast cancer and examines the link between BRCA1 deficiency and the basal-like phenotype. Search strategy. Data for this article were identified through MEDLINE and PubMed searches for published reports using the terms BRCA1, breast cancer, basal-like, chemotherapy, prognosis, and predictive markers. In some cases, due to the restriction of space, readers are referred to review articles to allow further reading. Only articles published in English were included.